Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis
Findings from this cost-effectiveness analysis suggested that, compared to atezo-cabo, atezo-beva brought better OS benefits to advanced HCC patients, but also brought higher economic burden, considering the willingness-to-pay threshold was $150 000 per QALY, atezo-beva was not considered cost-effective.
Authors
- Zhihua She
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-0852-1236)
- Heng Xiang
- Liting Wang (ORCID: https://orcid.org/0000-0001-6146-2549)
- Peng Ye (ORCID: https://orcid.org/0000-0001-7150-1265)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-6684-3794)
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
- Hunan Provincial Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1371/journal.pone.0337606
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00